Mangoceuticals, Inc. Financials
Mangoceuticals, Inc. (MGRX) reported $456K in revenue for fiscal year 2025, down 26.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
External financing, not customer revenue, is still the main engine keeping operations funded while a tiny sales base carries overhead.
FY2025 ended with cash of$1.5M and a current ratio of 1.7x, a sharp reset from FY2024's near-term liquidity squeeze. But that repair was funded by$7.3M of financing inflow while operations used-$5.9M , meaning liquidity improved even as the core business remained cash consumptive.
The business is still operating far below the scale needed to absorb its fixed cost base: FY2025 gross profit was only
This is more an equity-funded company than a debt-funded one: liabilities were just
Financial Health Signals
Mangoceuticals, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Mangoceuticals, Inc. scores -1.59, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($8.3M) relative to total liabilities ($891K). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Mangoceuticals, Inc. passes 2 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.
Mangoceuticals, Inc. reported a net loss of $20.6M while operations used $5.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Mangoceuticals, Inc. reported an operating loss of $18.0M against $104K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Mangoceuticals, Inc. generated $456K in revenue in fiscal year 2025. This represents a decrease of 26.0% from the prior year.
Mangoceuticals, Inc.'s EBITDA was -$16.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 112.4% from the prior year.
Mangoceuticals, Inc. reported -$20.6M in net income in fiscal year 2025. This represents a decrease of 137.1% from the prior year.
Mangoceuticals, Inc. earned -$2.17 per diluted share (EPS) in fiscal year 2025.
Cash & Balance Sheet
Mangoceuticals, Inc. held $1.5M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Mangoceuticals, Inc.'s gross margin was 54.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 6.8 percentage points from the prior year.
Mangoceuticals, Inc.'s ROE was -135.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 73.4 percentage points from the prior year.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
None of these metrics is reported for fiscal year 2025.
MGRX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| Revenue | $315K | $456K-26.0% | $616K-15.8% | $731K+8083.2% | $9K |
| Cost of Revenue | $30K | $54K-41.7% | $93K-39.8% | $155K+3688.2% | $4K |
| Gross Profit | $172K | $250K-34.1% | $380K-11.9% | $432K+8796.9% | $5K |
| SG&A Expenses | $2.3M | $3.8M+25.2% | $3.0M-9.6% | $3.3M+102.0% | $1.6M |
| Operating Income | -$12.3M | -$18.0M-126.2% | -$8.0M | N/A | -$2.0M |
| Interest Expense | N/A | $104K+655.6% | $14K+311.6% | -$6K-200.0% | $6K |
| Net Income | -$15.1M | -$20.6M-137.1% | -$8.7M | N/A | -$2.0M |
| EPS (Diluted) | — | -$2.17 | -$4.80 | -$8.58-4415.8% | -$0.19 |
Not reported in any period shown, so not listed: R&D Expenses, Income Tax.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
MGRX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|
| Total Assets | $16.1M+4.7% | $15.4M+1362.8% | $1.1M+4.7% | $1.0M |
| Current Assets | $1.5M+1947.0% | $76K-91.0% | $835K+20.3% | $695K |
| Cash & Equivalents | $1.5M+2434.1% | $59K-92.1% | $739K+8.2% | $683K |
| Inventory | N/A | N/A | $19K | N/A |
| Total Liabilities | $891K-37.5% | $1.4M+416.4% | $276K-29.1% | $389K |
| Current Liabilities | $891K-37.5% | $1.4M+575.3% | $211K-19.0% | $261K |
| Total Equity | $15.2M+9.0% | $13.9M+1700.1% | $775K+26.2% | $614K |
| Retained Earnings | -$40.6M-103.2% | -$20.0M-78.2% | -$11.2M-457.0% | -$2.0M |
Not reported in any period shown, so not listed: Accounts Receivable, Goodwill, Long-Term Debt.
MGRX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$3.9M | -$5.9M-20.3% | -$4.9M | N/A | -$1.3M |
| Capital Expenditures | N/A | N/A | N/A | $4K-91.8% | $43K |
| Free Cash Flow | N/A | N/A | N/A | N/A | -$1.4M |
| Investing Cash Flow | N/A | N/A | $65K+1947.1% | -$4K+91.8% | -$43K |
| Financing Cash Flow | N/A | $7.3M+76.1% | $4.1M | N/A | $2.0M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
MGRX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|
| Gross Margin | 54.9%-6.8pp | 61.7%+2.7pp | 59.0%+4.7pp | 54.3% |
| Operating Margin | -3954.3% | -1294.4% | N/A | -22279.7% |
| Net Margin | -4526.8% | -1413.6% | N/A | -22352.1% |
| Return on Equity | -135.8%-73.4pp | -62.4% | N/A | -325.4% |
| Return on Assets | -128.3%-71.7pp | -56.6% | N/A | -199.2% |
| Current Ratio | 1.74+1.7x | 0.05-3.9x | 3.96+1.3x | 2.67 |
| Debt-to-Equity | 0.060.0x | 0.10-0.3x | 0.36-0.3x | 0.63 |
| FCF Margin | N/A | N/A | N/A | -15545.6% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Mangoceuticals, Inc. Ranks
Frequently Asked Questions
What is Mangoceuticals, Inc.'s annual revenue?
Mangoceuticals, Inc. (MGRX) reported $456K in total revenue for fiscal year 2025. This represents a -26.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Mangoceuticals, Inc.'s revenue growing?
Mangoceuticals, Inc. (MGRX) revenue declined by 26.0% year-over-year, from $616K to $456K in fiscal year 2025.
Is Mangoceuticals, Inc. profitable?
No, Mangoceuticals, Inc. (MGRX) reported a net income of -$20.6M in fiscal year 2025.
What is Mangoceuticals, Inc.'s EBITDA?
Mangoceuticals, Inc. (MGRX) had EBITDA of -$16.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Mangoceuticals, Inc.'s gross margin?
Mangoceuticals, Inc. (MGRX) had a gross margin of 54.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Mangoceuticals, Inc.'s return on equity (ROE)?
Mangoceuticals, Inc. (MGRX) has a return on equity of -135.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Mangoceuticals, Inc.'s operating cash flow?
Mangoceuticals, Inc. (MGRX) recorded an outflow of $5.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Mangoceuticals, Inc.'s total assets?
Mangoceuticals, Inc. (MGRX) had $16.1M in total assets as of fiscal year 2025, including both current and long-term assets.
What is Mangoceuticals, Inc.'s current ratio?
Mangoceuticals, Inc. (MGRX) had a current ratio of 1.74 as of fiscal year 2025, which is generally considered healthy.
What is Mangoceuticals, Inc.'s debt-to-equity ratio?
Mangoceuticals, Inc. (MGRX) had a debt-to-equity ratio of 0.06 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Mangoceuticals, Inc.'s return on assets (ROA)?
Mangoceuticals, Inc. (MGRX) had a return on assets of -128.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Mangoceuticals, Inc.'s Altman Z-Score?
Mangoceuticals, Inc. (MGRX) has an Altman Z-Score of -1.59, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Mangoceuticals, Inc.'s Piotroski F-Score?
Mangoceuticals, Inc. (MGRX) has a Piotroski F-Score of 2 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Mangoceuticals, Inc.'s earnings high quality?
Mangoceuticals, Inc. (MGRX) reported a net loss of $20.6M while operations used $5.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Mangoceuticals, Inc. cover its interest payments?
Mangoceuticals, Inc. (MGRX) reported an operating loss of $18.0M against $104K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.